Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing

ALK+ and ROS1+ NSCLC: Optimising patient outcomes

Date

14 Sep 2020

Session

Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing

Presenters

Todd Bauer

Authors

T. Bauer

Author affiliations

  • Sarah Cannon Research Institute, 37203 - Nashville/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Welcome and introduction

Presenter: Rosario Garcia Campelo

Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.